drugset / Trial / NCT02371590
Lenalidomide and Obinutuzumab for Previously Untreated CLL
Phase 2
Withdrawn
University of California, San Diego
Celgene Corporation · collabGenentech, Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
This is phase 1/2 study for patients with CLL or (SLL) who have not been previously treated. This study will evaluate whether obinutuzumab and lenalidomide is safe and tolerable in this setting and induce complete clinical responses.
Timeline
- Start
- 2018-02
- Primary completion
- 2019-12
- Completion
- 2022-12
Outcome
Outcome not reported
Stopped: “Study Not Activated Due to Contract Issues”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenalidomide | Other / unclassified | 25 mg | Oral |
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |